Pomegranate juice for mild-to-moderate ulcerative colitis
Official title: Effect of Pomegranate Juice on Gut Inflammation, Quality of Life and the Gut Microbiome in Patients With Ulcerative Colitis: A Pilot Study
Run by University of California, Los Angeles · NCT07115862 · Data updated 2026-11-12
The goal is to see if drinking 237 ml of pomegranate juice every day for 8 weeks lowers inflammation and changes gut microbes in adults with mild-to-moderate ulcerative colitis.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | University of California, Los Angeles Academic / other |
| Drugs / interventions | methotrexate, prednisone |
| Locations | 2 sites (Los Angeles, California and 1 other locations) |
| Status | Recruiting |
| Started | October 15, 2025 |
| Main results expected | October 15, 2027 |
| Study ends | October 15, 2027 |
| Registry record updated | December 9, 2025 |
| Trial ID | NCT07115862 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) with mild-to-moderate, biopsy-confirmed ulcerative colitis who have supportive evidence of active inflammation, are on stable allowed medications, and follow a low-polyphenol/low-fiber diet are the intended candidates.
✕Probably not a fit
Patients with severe ulcerative colitis, unstable or recently changed immunosuppressive therapy, higher-than-allowed steroid doses, or no evidence of active inflammation are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, controlled 16-week delayed-start trial enrolls adults with mild-to-moderate, biopsy-proven ulcerative colitis and evidence of active inflammation. Participants are randomly assigned to consume 237 ml of pomegranate juice daily for the first 8 weeks while the delayed-start group follows their habitual diet, then the groups switch for the second 8-week phase. Outcomes include fecal calprotectin and partial Mayo score for gut inflammation and quality of life, blood inflammatory and oxidative stress markers, and gut microbiota composition and function (including urolithin metabolites, SCFAs, and bile acids). The delayed-start design provides a control comparison and an exploratory follow-up to see whether any effects persist after stopping juice.
Why it matters
Potential benefit: If successful, daily pomegranate juice could reduce gut inflammation, improve symptoms and quality of life, and shift the gut microbiota toward a healthier profile.
How similar studies have gone: Preclinical work and small human studies of pomegranate polyphenols suggest anti-inflammatory and microbiome effects, but robust clinical evidence specifically in ulcerative colitis is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * • Adults ≥ 18 yo * Following a low-polyphenol and fiber diet (\< 3 servings of fruits/vegetables per day) * Mild-to-moderate UC at the time of screening (2 ≤ partial Mayo scores ≤ 5) * Supportive evidence of active inflammation (hsCRP \>1 mg/L, fecal calprotectin \>50 µg/g stool, or abnormal lower endoscopy) in individuals with biopsy-proven UC * Patients on 5-aminosalicylates must be on a stable dose for ≥ 4 weeks prior to screening * Patients on treatment with immunosuppressive therapy (e.g., azathioprine/6-mercaptopurine, methotrexate) must be on stable dose for 8 weeks prior to baseline visit * At the time of baseline visit, patients may be on no more than 20 mg/day of prednisone and 9 mg/day of budesonide MMX * Subjects must read and sign the Institutional Review Board-approved written informed consent prior to the initiation of any study specific procedures or enrollment. A subject will be excluded for any condition that might compromise the ability to give truly informed consent. Exclusion Criteria: * • Non-English speaker * Vegetarian/vegan * Known pomegranate allergy * Documented chronic disease besides UC, including diabetes, renal or liver diseases, metabolic syndrome, active cancer, MI or stroke, history of gastric bypass * Patients with CD, indeterminate/severe to fulminant colitis * History of colectomy or colonic dysplasia * Presence of ileal pouch or ostomy * Evidence of active bacterial or viral gastroenteritis as indicated by positive stool studies for ova \& parasites, Clostridium difficile, and stool culture * Recent hospitalizations (within 2 weeks of screening) for UC requiring IV steroids * Presence of the following labs indicative of severe colitis: a. Hemoglobin \< 8.0 g/dl b. Albumin \< 3.0 g/dl * Recent systemic antibiotics use (within 3 months of screening) or active use of anti-diarrheal medications * Taking supplements known to affect metabolism or gut microbiota composition (probiotics, fiber, etc.), unless willing to stop for the study duration * Use of Total Parenteral Nutrition (TPN) * Use of cyclosporine, tacrolimus, or thalidomide within 2 months prior to screening * Taking exogenous hormones (e.g., hormone replacement therapy) * Recent weight fluctuations (\>10% in the last 6 months) * Smoker or living with a smoker * Use of \>20 g of alcohol per day * Unable or unwilling to comply with the study protocol (including unwillingness to avoid watermelon and other lycopene-rich foods for the whole duration of the study) * Unable to provide consent
Where it's running
-
UCLA Center for Human Nutrition
Los Angeles, California, United States Recruiting -
West Los Angeles VA Medical Center
Los Angeles, California, United States Not yet recruiting
Study contacts
- Principal investigator: Zhaoping Li, MD, PhD — University of California, Los Angeles
- Study coordinator: Tatiana Diacova, PhD, MS, RDN
- Email: tdiacova@mednet.ucla.edu
- Phone: 310-206-8292
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Mediterranean Diet and Time-Restricted Feeding in Ulcerative Colitis in Remission
This study tests whether a Mediterranean diet, with or without an 8-hour eating window, helps gut health and quality of life in adults with ulcerative colitis in remission.
-
Guselkumab in Moderate-to-Severe Ulcerative Colitis: Real-World Experience
This real-world study tests whether guselkumab helps adults with moderate-to-severe ulcerative colitis and how safe it is for them.
-
BDHK-2009 safety test in healthy adults
This early-stage test checks if BDHK-2009 tablets are safe and tolerable in healthy adults aged 18–55 compared with placebo.
-
ButyMixx for Ulcerative Colitis in Remission
This study tests ButyMixx, a supplement with sodium butyrate and a beneficial yeast, to see if it helps people with ulcerative colitis in remission feel better and keep inflammation low.
-
Partial enteral nutrition to help IBD patients at nutritional risk maintain weight
We’re testing whether adding an oral nutritional supplement (LH VIOLA) to standard counseling helps adults with IBD who are at risk of malnutrition keep or gain weight over 16 weeks.
-
Etrasimod for ulcerative colitis in older adults
This study will test whether etrasimod is safe and helps control active ulcerative colitis in older adults.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.